Targeting triple negative breast cancer stem cells using nanocarriers

Area of Science:

• Oncology
• Nanomedicine
• Cancer Biology

Background:

• Breast cancer is heterogeneous, with subtypes like triple-negative breast cancer (TNBC) lacking ER, PR, and HER2 receptors.
• TNBC exhibits aggressive behavior, high recurrence rates, and resistance to conventional therapies.
• Breast cancer stem cells (BCSCs) drive TNBC initiation, progression, and treatment resistance.

Purpose of the Study:

• To review nanoparticle-based therapeutic strategies for targeting BCSCs in TNBC.
• To address challenges in BCSC-targeted therapy, including off-target effects and poor bioavailability.
• To explore how nanocarriers can improve TNBC treatment efficacy and reduce systemic toxicity.

Main Methods:

• Review of current literature on BCSCs in TNBC.
• Analysis of various nanocarrier systems and their applications in targeting TNBC BCSCs.
• Discussion of key molecular targets within BCSCs, including self-renewal pathways and survival proteins.

Main Results:

• BCSCs are critical targets for effective TNBC treatment.
• Nanoparticle-based therapies offer a viable approach to overcome limitations of conventional BCSC-targeting agents.
• Targeting BCSCs via nanocarriers can enhance drug delivery, minimize toxicity, and improve therapeutic outcomes.

Conclusions:

• Nanoparticle-based strategies represent a promising avenue for overcoming therapeutic challenges in TNBC.
• Targeted delivery to BCSCs using nanocarriers holds potential for improving survival rates and reducing recurrence in TNBC patients.
• Further research into nanocarrier design and BCSC targeting is crucial for advancing TNBC treatment.